Ranjit K Goudar

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Management options for malignant pleural mesothelioma: clinical and cost considerations
    Ranjit K Goudar
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27701, USA
    Drugs 67:1149-65. 2007
  2. ncbi Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition)
    Momen M Wahidi
    Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Box 3683, Durham, NC 27710, USA
    Chest 132:94S-107S. 2007
  3. ncbi Hypoxia, angiogenesis, and lung cancer
    Ranjit K Goudar
    Department of Medicine, Duke University Medical Center, Box 3841, Durham, NC 27710, USA
    Curr Oncol Rep 10:277-82. 2008

Detail Information

Publications3

  1. ncbi Management options for malignant pleural mesothelioma: clinical and cost considerations
    Ranjit K Goudar
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27701, USA
    Drugs 67:1149-65. 2007
    ..MPM treatment is a costly public health issue; after efficacy is proven, additional studies are needed to measure the cost effectiveness of MPM treatment regimens...
  2. ncbi Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition)
    Momen M Wahidi
    Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Box 3683, Durham, NC 27710, USA
    Chest 132:94S-107S. 2007
    ..The solitary pulmonary nodule (SPN) is a frequent incidental finding that may represent primary lung cancer or other malignant or benign lesions. The optimal management of the SPN remains unclear...
  3. ncbi Hypoxia, angiogenesis, and lung cancer
    Ranjit K Goudar
    Department of Medicine, Duke University Medical Center, Box 3841, Durham, NC 27710, USA
    Curr Oncol Rep 10:277-82. 2008
    ..Combinations of antiangiogenic drugs and conventional cytotoxic chemotherapy are currently under development...